ArticleMolecular psychiatry2026
Subtyping psychotic disorders using a data-driven approach reveals divergent cortical and cellular signatures.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
9 authors.
Funding
Abstract
Structural brain abnormalities in psychosis are well-replicated but heterogenous posing a barrier to uncovering the pathophysiology, etiology, and treatment of psychosis. To parse neurostructural heterogeneity and assess for the presence of anatomically-derived subtypes, we applied a data-driven method, similarity network fusion (SNF), to structural neuroimaging data in a broad cohort of individuals with psychosis (schizophrenia spectrum disorders (SSD) n = 280; bipolar disorder with psychotic features (BD) n = 101). SNF identified two transdiagnostic subtypes in psychosis (subtype 1: n = 158 SSD, n = 75 BD; subtype 2: n = 122 SSD, n = 26 BD) that exhibited divergent patterns of abnormal cortical surface area and subcortical volumes. Compared to controls (n = 243), subtype 1 showed moderate enlargement of surface area in frontal and parietal areas and larger dorsal striatal volumes, whereas subtype 2 demonstrated markedly smaller surface areas in frontal and temporal areas and subcortical volumes, including hippocampus, amygdala, thalamus and ventral striatum. When comparing subtypes on clinical characteristics, subtype 2 demonstrated more severe negative symptoms, greater neuropsychological impairment, and lower estimated premorbid intellectual functioning. Integrating cell-type data imputed from gene expression in the Allen Human Brain Atlas revealed an association between interregional glial cell and parvalbumin-expressing interneuron abundance and surface area expansion in subtype 1, yet cortical thinning in subtype 2. The largest deviations from controls were present in subtype 2 surface area that spatially coupled with layer 5 glutamatergic neuron abundance, critical for corticostriatal connectivity. These outcomes indicate early diverging neurodevelopmental trajectories of psychosis subtypes, as evidenced by opposing patterns in surface area, cellular fingerprints, and subcortical volumes.
Identifiers
42493610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.